Bavarian Nordic A/S – OTC:BVNRY
Bavarian Nordic A/S stock price today
$12.31
+3.36
+37.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Bavarian Nordic A/S stock price monthly change
+3.47%
month
Bavarian Nordic A/S stock price quarterly change
+3.47%
quarter
Bavarian Nordic A/S stock price yearly change
+0.90%
year
Bavarian Nordic A/S key metrics
Market Cap | 2.38B |
Enterprise value | 2.97B |
P/E | -41.08 |
EV/Sales | 0.94 |
EV/EBITDA | 12.97 |
Price/Sales | 3.59 |
Price/Book | 1.58 |
PEG ratio | -1.62 |
EPS | 13.78 |
Revenue | 6.64B |
EBITDA | 2.20B |
Income | 984.37M |
Revenue Q/Q | -33.59% |
Revenue Y/Y | 62.73% |
Profit margin | -11.03% |
Oper. margin | -2.25% |
Gross margin | 53.99% |
EBIT margin | -2.25% |
EBITDA margin | 33.15% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBavarian Nordic A/S stock price history
Bavarian Nordic A/S stock forecast
Bavarian Nordic A/S financial statements
| Jun 2023 | 1.98B | 538.07M | 27.09% |
|---|---|---|---|
| Sep 2023 | 1.37B | -340.64M | -24.75% |
| Dec 2023 | 2.44B | 901.39M | 36.8% |
| Mar 2024 | 831.47M | -114.45M | -13.76% |
| 2025 | 4.76B | 225.41M | 4.73% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-05-09 | 0.09 | 0.25 |
|---|
| Jun 2023 | 14993241000 | 5.30B | 35.4% |
|---|---|---|---|
| Sep 2023 | 13399238000 | 4.06B | 30.33% |
| Dec 2023 | 14353213000 | 4.01B | 27.96% |
| Mar 2024 | 13620931000 | 3.44B | 25.3% |
| Jun 2023 | 442.48M | -1.03B | 149.92M |
|---|---|---|---|
| Sep 2023 | 305.97M | -100.26M | -11.55M |
| Dec 2023 | 585.44M | -143.71M | 13.21M |
| Mar 2024 | 435.22M | -1.04B | -10.72M |
Bavarian Nordic A/S alternative data
| Aug 2023 | 1,040 |
|---|---|
| Sep 2023 | 1,354 |
| Oct 2023 | 1,354 |
| Nov 2023 | 1,354 |
| Dec 2023 | 1,351 |
| Jan 2024 | 1,351 |
| Feb 2024 | 1,351 |
| Mar 2024 | 1,379 |
| Apr 2024 | 1,379 |
| May 2024 | 1,379 |
| Jun 2024 | 1,381 |
| Jul 2024 | 1,381 |
Bavarian Nordic A/S other data
-
What's the price of Bavarian Nordic A/S stock today?
One share of Bavarian Nordic A/S stock can currently be purchased for approximately $12.31.
-
When is Bavarian Nordic A/S's next earnings date?
Unfortunately, Bavarian Nordic A/S's (BVNRY) next earnings date is currently unknown.
-
Does Bavarian Nordic A/S pay dividends?
No, Bavarian Nordic A/S does not pay dividends.
-
How much money does Bavarian Nordic A/S make?
Bavarian Nordic A/S has a market capitalization of 2.38B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 124.14% to 7.06B US dollars. Bavarian Nordic A/S earned 1.48B US dollars in net income (profit) last year or $0.25 on an earnings per share basis.
-
What is Bavarian Nordic A/S's stock symbol?
Bavarian Nordic A/S is traded on the OTC under the ticker symbol "BVNRY".
-
What is Bavarian Nordic A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bavarian Nordic A/S?
Shares of Bavarian Nordic A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Bavarian Nordic A/S have?
As Jul 2024, Bavarian Nordic A/S employs 1,381 workers, which is 0% more then previous quarter.
-
When Bavarian Nordic A/S went public?
Bavarian Nordic A/S is publicly traded company for more then 12 years since IPO on 30 May 2013.
-
What is Bavarian Nordic A/S's official website?
The official website for Bavarian Nordic A/S is bavarian-nordic.com.
-
How can i contact Bavarian Nordic A/S?
Bavarian Nordic A/S can be reached via phone at +45 33 26 83 83.
Bavarian Nordic A/S company profile:
Bavarian Nordic A/S
bavarian-nordic.comExchange:
OTC
Full time employees:
917
Industry:
Biotechnology
Sector:
Healthcare
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Philip Heymans Alle 3
Hellerup, 2900
Hellerup, 2900
:
ISIN: US0717711099
:
